TAT-11: Pretargeted Ac-225 Radioimmunotherapy Strategies
In pre-targeting, the antibody is first injected to sufficient quantities to nearly saturate the receptors. After any excess antibodies have been rapidly cleared, the radiolabeled molecules are injected to click into the antibody at the site of the tumor. This technique was tried first with Lu177 conjugates, then Ac225 in mice. They observed comparable uptake compared with traditionally labeled injection.
Human trials will be starting soon.
Presented by: Jason S. Lewis, MD, Vice Chair for Research, Chief of the Radiochemistry and Imaging Sciences Service, and Director of the Radiochemistry and Molecular Imaging Probe Core Facility, Memorial Sloan Kettering Cancer Center
Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10) April 1 - April 4, 2019 - Ottawa, ON, Canada